United StatesGermany's Merck KGaA has agreed to acquire Bio-Techne, a supplier of laboratory tools, for $11.3 billion. This acquisition marks Merck's largest deal since its previous purchase of Sigma-Aldrich. The transaction aims to strengthen Merck's position in areas such as proteins, spatial biology, and cell and gene therapy. The merger is expected to enhance Merck's capabilities in life sciences research and development. No specific details about the terms of the deal or potential regulatory approvals were provided in the article.
Bias read (Center): The article reports on a corporate acquisition without any political commentary, framing, or bias. It focuses solely on the business implications of the deal and does not take a stance on the matter.
